The Benefits of Immediate Treatment Initiation Without Immunovirological Data Compared to Conventional BIC / FTC / TAF Treatment in Naive Patients With Type 1 HIV (Human Immunodeficiency Virus) Infection

NCT05606055 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

100

Enrollment

OTHER

Sponsor class

Conditions

HIV-1-infection

Interventions

DRUG: BIC/FTC/TAF: Bictegravir/emtricitabina/tenofovir alafenamida fumarato

Sponsor

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz